cp wire

CP Wire Articles

Farxiga Meets One Primary Endpoint in Large Ph III Cardiovascular Outcomes Trial in 17,000 Patients with Type 2 Diabetes

AstraZeneca on 9/24/18 announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin), the broadest SGLT-2 inhibitor CVOT... read more

Mon, 09/24/18 - 09:36 am
Gilead to Launch Authorized Generic Versions of Epclusa and Harvoni for Chronic Hepatitis C


Gilead Sciences, Inc. (NASDAQ: GILD) announced on 9/24/18 plans to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir... read more

Mon, 09/24/18 - 09:22 am
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
  • Exelixis is eligible to receive a milestone payment of $40 million for the approval of the second-line treatment of HCC
  • In May of 2018, the FDA accepted for filiing an sNDA for... read more
Fri, 09/21/18 - 09:42 am
Ex-Novartis Chief Joins uBiome to Help Launch Discovery and Development Business
  • Company expanding into drug discovery, development and commercialization
  • Ubiome also announced it has raised $83 million in Series C financing


uBiome announced on 9/... read more

Fri, 09/21/18 - 09:15 am
MicuRx Recieves Fast Track and QIDP Designations for MRSA Antiobiotics


MicuRx Pharmaceuticals, Inc. announced on 9/21/18 the receipt of the qualified infectious disease product (QIDP) classification and grant of fast track... read more

Fri, 09/21/18 - 09:05 am

Pages